Study objectives: To describe our clinical experience with autoadjusting positive airway pressure (APAP) trials carried out on patients with moderate-to-severe obstructive sleep apnea (OSA). Methods: Consecutive CPAP-naïve adults underwent a non-attended home APAP trial (ResMed, Autoset, Spirit). Diagnoses of OSA were established by simplified polygraphy. Results: Data from 208 men and 71 women. The median age (interquartile range) was 51 years (41-59), with an Epworth Sleepiness Scale score of 13.5 (9-19), body mass index of 33 kg/m 2 (29-38) and respiratory disturbance index (RDI) of 53 events/h (35-74). The APAP trial results included: hours used per night, 5.5 (4-7); 95 th percentile pressure, 10.6 cm H 2 O (9.4-11.7); 95 th percentile leak, 0.3 L/sec (0.1-0.6); residual RDI, 6.2 events/h (3.9-11.4); and percentage change in RDI,[87][88][89][90][91][92][93]. The proportion of patients with residual RDI >10 events/h was 29% (95% CI 23.6-34.3). Adherence (≥70% of nights and ≥4 h/night) was observed in 72.4% of subjects (95% CI 67-78).
C ontinuous positive airway pressure (CPAP) is the treatment of choice for patients with moderate-to-severe obstructive sleep apnea (OSA). 1, 2 According to the standard, 2,3 the pressure applied during long-term treatment should be determined manually by a technician on the basis of a continuous polysomnographic recording; however, autoadjusting positive airway pressure (APAP) titration, particularly in the home, has been introduced as a practical strategy that saves time and reduces costs. 4, 5 Recently, the American Academy of Sleep Medicine (AASM) published the practice parameters for the use of APAP devices for titrating pressures and treating adult patients with OSA. 6 That document establishes that APAP devices may be used in an unattended manner to determine a fixed CPAP treatment pressure for patients with moderate-to-severe OSA without significant comorbidities, such as chronic heart failure, chronic obstructive pulmonary disease, central sleep apnea syndromes, or hypoventilation syndromes. 6 APAP titration may provide increased access to diagnosis and treatment of OSA that is not constrained by the availability of sleep laboratories, an issue that is of particular importance for developing countries.
Regarding the diagnostic methods used, portable monitors have been widely evaluated and "The Clinical Guidelines for the Use of Unattended Portable Monitors in the Diagnosis of OSA in Adult Patients," published by the AASM, establishes that portable monitoring may be used as an alternative to polysomnography for diagnosing OSA in patients with a high pretest probability of moderate-to-severe OSA. 7 Mulgrew et al 8 recently demonstrated that in the initial management of patients with a high probability of OSA, polysomnography confers no advantage over the ambulatory approach in terms of diagnosis and CPAP titration. There is, then, a growing body of evidence that supports the use of simplified diagnostic and titration methods that, for a certain group of patients, may be just as effective as the standard recommendations 8 ; however, little is yet known about the APAP titration process following a simplified diagnostic approach.
In our sleep medicine facility, we use such a simplified diagnostic approach in patients with a high probability of OSA. In this approach, diagnoses of OSA are established using the Remmers Sleep Recorder (SagaTech Electronics Inc., Calgary, Patients with APAP adherence tended to require higher CPAP pressures, had higher rates of residual RDI, and had a lower percentage change in RDI than those with no adherence. As the 95 th percentile CPAP pressure increased so too did residual RDI. conclusions: The APAP trial was effective in decreasing RDI with an acceptable adherence rate; however, residual OSA was a frequent finding. Our results support that in up to one-third of patients evaluated by a simplified diagnostic approach, CPAP titration based on 95 th percentile pressure may not be sufficient if residual RDI <10 events/h is considered as a therapeutic target. L Torre-Bouscoulet, MS Meza-Vargas, A Castorena-Maldonado, et al Alberta, Canada), which calculates a respiratory disturbance index (RDI) on the basis of oxygen desaturation events. Once the diagnosis is established, CPAP titration is performed by means of a 1-week, non-attended APAP trial carried out in a home setting.
Thus, the objectives of this study were, first, to describe our clinical experience with APAP trials performed on patients with moderate-to-severe OSA who were evaluated using a simplified diagnostic approach; and, second, to describe early APAP adherence rates and the frequency of residual OSA, and identify their associated factors.
PAtieNtS AND MethoDS
This study was approved by the institutional review board. Data were collected retrospectively and appropriate care was taken to protect patients' privacy and identity.
We analyzed data from consecutive CPAP-naïve patients with moderate-to-severe OSA who underwent a non-attended home setting APAP trial following a simplified diagnostic approach. The study was done in a single tertiary care center in Mexico City, where a simplified diagnostic approach is used as part of a continuum of care by sleep specialists and highly trained CPAP clinical personnel as a means of improving access to diagnosis and treatment, as we have a large and growing waiting list for sleep studies. All patients completed a standardized questionnaire on sleep symptoms that included the Epworth Sleepiness Scale score (ESS) and anthropometric measurements. In addition, they were evaluated clinically by 2 medical sleep specialists, who determined the clinical probability of OSA based on the adjusted neck circumference. 9 An adjusted neck circumference > 48 cm was considered indicative of a high pretest probability. Patients with a high probability of OSA but no comorbid conditions-such as cardiac failure, chronic obstructive pulmonary disease or morbid obesity-were scheduled to complete a simplified respiratory polygraphy (SRP), using a portable device in an attended setting at the sleep unit. The SRP was done using the aforementioned Remmers Sleep Recorder, which measures oxygen saturation, respiratory effort, airflow, snoring, and leg movements. This device calculates an RDI on the basis of oxygen desaturation events. An RDI ≥ 15 events/h, as measured by the Remmers Sleep Recorder, has a sensitivity of 98% and a specificity of 88% for diagnosis of moderate-to-severe obstructive sleep apnea. 10 We had previously verified the performance of this particular model of portable monitor in Mexico City at an altitude of 2,240 meters above sea level (7,350 feet) , where an intraclass correlation coefficient between the polysomnographic apnea hypopnea index (AHI) and the RDI of 0.89 (95% confidence interval, 0.83-0.96) was found. 11 The quality of the SRP was verified through a visual analysis performed by an experienced sleep technician. In this study, we did not include data from patients examined using polysomnography.
In all cases, the goals of the APAP trial centered on CPAP titration and evaluating early adherence to APAP. Patients we considered apt candidates for the APAP trial were: (1) those with severe OSA (ESS ≥ 11 and RDI ≥ 30 events/h); (2) those with no sleepiness (ESS < 11) but an RDI ≥ 30 events/h; and, (3) patients with RDIs between 5 and 30 and ESS ≥ 11. Because the usefulness of an APAP trial for diagnosing OSA in patients with high pretest probability has been reported, 12 we also considered as candidates for the APAP trial, (4) patients with habitual snoring, observed apneas, neck size > 43 cm (adjusted neck circumference > 48 cm with or without arterial hypertension), and ESS ≥ 11 (even if they did not undergo SRP).
The APAP trial lasted 7 consecutive nights in a non-attended home setting, though it was extended (median = 19 nights) in 33 cases. All APAP trials were done using the same commercial brand of APAP device, the ResMed, Autoset, Spirit (ResMed Inc, San Diego, CA, USA). The APAP device was programmed to supply 4 cm H 2 O as the minimum positive pressure and 3 cm H 2 O above the predicted pressure obtained by our local formula as the maximum pressure. 13 All patients received detailed information concerning CPAP treatment and the nasal mask to be used was selected individually. One week after initiating APAP, the patients were routinely seen in the CPAP clinic, and the information stored in the APAP machines was downloaded to provide data on usage, mask leakage, pressure and AHI, all of which were entered in a data base for later analysis. In order to be consistent throughout this article, the AHI obtained by the APAP device will be referred to as RDI. Adherence during the APAP trial was defined as using the APAP ≥ 70% of nights and ≥ 4 h/night.
14 As suggested by Baltzan et al, 15 residual OSA was defined as residual RDI ≥ 10 events/h. The percentage change in RDI was obtained using the following formula: (Diagnostic RDI -residual RDI obtained from the APAP device / Diagnostic RDI)*100.
Statistical Analysis
Most variables showed non-normal distributions, a circumstance that led us to present the data in the form of median and interquartile ranges (IQR). Ratios are expressed as percentages and 95% confidence intervals (95% CI). Differences between the 2 groups (adherent vs. nonadherent and residual RDI <10 vs. > 10 events/h) were probed using the Wilcoxon rank-sum test. To explore the variables associated with adherence and residual OSA, a univariate logistic analysis was performed and only those variables statistically-associated with the dependent variables were then tested using multiple logistic regression models. The strength of the association is expressed as odds ratios and 95% confidence intervals. Associations between continuous variables were explored by calculating the Spearman correlation coefficient. The level of statistical significance for each test was p < 0.05. Analysis was performed using a commercial statistics package (Stata, release 9.2, StataCorp, College Station, TX, USA).
ReSULtS
Data from 208 men and 71 women (n = 279) were included. Most patients (89%) completed an SRP. Thirty-one patients (11%) were considered apt candidates for the APAP trial based only on high clinical probability using ESS ≥ 11 and an adjusted neck circumference > 48 cm. The median age for the entire group was 51 years (41-59), the ESS score was 13.5 (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , the body mass index was 33 kg/m 2 (29-38), and RDI was 53 events/h (35-74). The general characteristics of the subjects and the results of the APAP trial are shown in Table 1 .
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Data from patients with adherence were compared with those from patients with no adherence ( Table 2) . The latter had a lower 95 th percentile pressure and residual RDI, as well as a higher SpO 2 during the SRP and a higher percentage change in RDI than patients with adherence. The distribution of residual RDI is shown in Figure 1 . The entire group was divided according to residual RDI into those with RDI ≥ 10 events/h (the criteria used to define residual OSA) and those with RDI < 10 events/h (Table 4) . For the entire group, the proportion of patients with residual OSA was 29% (95% CI 24-34), while it was 31% (95% CI 25-38) for patients with adherence. Patients with residual OSA had a lower body mass index and percentage change in RDI but a higher 95 th percentile pressure than patients with no residual OSAS ( We found no difference in the proportion of patients with adherence (73%, 95% CI 68-79 vs. 66%, 95% CI 47-82, p = 0.29), residual RDI (6.5 events/h, IQR 4-11 vs. 5 events/h, IQR 2.5-13, p = 0.45), or in the proportion of residual OSA (29%, 95% CI 24-35 vs. 26%, 95% CI 10-42, p = 0.67) between those studied using SRP and those evaluated without SRP.
DiScUSSioN
The most important findings were: (1) the APAP device tested in this study significantly reduced RDI in patients with moderate-to-severe OSA who were evaluated using a simplified diagnostic approach; (2) an early adherence rate of 72.4% was seen in this group of patients; (3) patients with APAP adherence tended to require higher CPAP pressures, had a higher rate of residual RDI, and had a lower percentage change in RDI as well as lower SpO 2 during the night, than those with no adherence; (4) almost one-third of patients continued with residual OSA, defined as a residual RDI >10 events/h; and, (5) even after adjusting for potential confounders, patients with residual OSA had a higher 95 th percentile pressure than those with no residual OSA.
In this study, we identified an adherence rate of 72.4% using a conventional definition (≥ 70% of nights and ≥ 4h/night). Patients who showed no adherence during the APAP trial may well represent a high-risk population for no long-term adherence. Available evidence suggests that patients' initial experience with CPAP treatment during the titration process may be a crucial factor in determining their subsequent use of this treatment modality. 16, 17 Patients evaluated through a simplified diagnostic approach with no adherence during the APAP trial should undergo full polysomnography 18 with manual titration, since other comorbidities, such as hypoventilation, central sleep apnea or periodic breathing, could be interfering with the correct the better the APAP adherence, though patients with adherence had a higher 95 th percentile pressure compared to patients with no adherence. It would appear that patients with adequate adherence have higher upper airway resistance than those with no adherence; nonetheless, we found no difference in the severity of the disease (diagnostic ESS and RDI) between patients with or without APAP adherence.
The usefulness of APAP in patients with OSA has been amply demonstrated in other studies. 5, 19 An interesting finding by Ayas diagnosis, optimal CPAP pressure and the adherence process. This study did not include patients with suspected comorbidity to the aforementioned simplified approach. Interestingly, patients with APAP adherence tended to require higher CPAP pressures, had a higher rate of residual RDI, and had a lower percentage change in RDI, as well as a lower SpO 2 during the night, than those with no adherence. Although difficult to analyze, it would appear that the smaller the percentage change in RDI and, therefore, the higher the residual RDI, There is only limited data to support the finding that the residual RDI obtained from the APAP device is a reliable marker of residual or persistent OSA. Woodson et al 23 reported, for a small number of patients, a strong correlation between residual RDI from the APAP device against that obtained simultaneously by polysomnography (r = 0.77); however, in that study, the APAP overestimated RDI by 1.4 events/h. Although the polysomnographic residual RDI should be considered as the gold standard, it would be an impractical approach for determining residual OSA, if we take into account the need to simplify diagnostic and titration methods.
The long-term impact of residual OSA is not yet fully understood. An elegant randomized study by Becker et al 25 demonstrated that subtherapeutic CPAP (with a mean reduction of 50% in RDI) did not result in a decrease in mean blood pressure. Indeed, Peker et al, 26 in a 7-year follow-up study, reported that incomplete treatment was not found to be associated with a reduction in the incidence of cardiovascular diseases. These studies and others 27 emphasize the importance of highly effective forms of treatment. In our study, the percentage change in RDI in the entire group was 87%, but it was only 71% in patients with residual OSA. One might argue that this reduction of RDI observed in patients with residual OSA (71%) would be insufficient to reduce the high cardiovascular risk seen in patients with OSA, 28 however, the residual RDI obtained while the patient is wearing the CPAP may not have the same biological implications as that obtained during the diagnostic study; moreover, the residual RDI seen in this short-term trial does not necessarily reflect the behavior of residual RDI over time. It has been recognized in patients with OSA that, as the functional residual capacity increases with positive pressure, so too does the SpO 2 during the night, 29 an effect that may prevent the detrimental outcomes associated with intermittent hypoxemia. In accordance with this idea, we found no differences either in mean SpO 2 during the night or in total sleep time at < 90% SpO 2 between patients with or without residual OSA. Some studies et al 20 in a meta-analysis that included 282 patients, was that no differences were observed in the reduction of RDI between APAP vs. conventional CPAP. If this proves true, then the residual RDI and, therefore, the frequency of residual OSA seen in our study, could be no different from those obtained using manual titration. The residual RDI found in our patients (6.2 events/h, IQR 3.9-9.7) was similar to that reported in other studies in which APAP titration was carried out. 21 Though no widely-accepted definition of residual OSA exists, the traditional cut-off point of RDI > 5 events/h could be considered as such 22 ; but given that there are some data to support that the residual RDI obtained by the APAP device could be overestimated by 1-2 events/h, 23 in this study we considered a cut-off point for RDI of > 10 events/h as a definition of residual OSA. Contrary to Baltzan et al, 15 who reported a residual OSA prevalence of 17%, we observed that almost onethird of patients (29%) showed residual OSA using the same diagnostic criteria (RDI > 10 events/h); however, the residual RDI in that study was determined by polysomnography, whereas in ours it was done by means of the APAP device. Stammnitz et al 24 also reported a residual OSA prevalence of 17% in a small number of patients whose residual RDI was determined using the APAP device, but a different diagnostic criteria (residual RDI > 5 events/h). In our patients, the delta between maximal programmed CPAP pressure and the 95 th percentile pressure (maximal programmed minus 95 th percentile pressure) was statistically lower in patients with residual OSA (4 cm H 2 O, IQR 2-6) than in those with no residual OSA (5.5 cm H 2 O, IQR 3-8); however, it is unlikely that a delta of 4 cm H 2 O is the reason for such a high residual RDI. Indeed, delta did not remain associated with residual OSA in the multivariate analysis. On the other hand, central sleep apnea might be participating in the high residual RDI seen in some patients, and may be associated, at least in part, with the altitude (2,240 meters) at which this study was done. However, the cut-off point of residual RDI that should be deemed significant to explore central sleep apnea as a contributing factor for residual RDI is unknown. 
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have suggested that intermittent hypoxemia, as determined by the oxygen desaturation index, could be even more important as a factor of cardiovascular damage than the breathing pauses per se. 30, 31 In the meantime, the long-term CPAP prescription based on the 95 th percentile pressure 21 provided by the device used in this study will not assure an optimum CPAP pressure in terms of residual OSA.
The frequency of residual OSA was 29% for the entire group, but was higher (31%) in patients with adequate APAP adherence; that is, the residual OSA concept is even more relevant in patients with adherence, since they are the ones who benefit most from CPAP treatment.
Our study has certain limitations; first, data were collected retrospectively and we did not have a comparison group that used manual CPAP titration; two issues that limit the external validity of our results. Second, we did not routinely obtain ESS scores after the APAP trial was completed, so we are not able to affirm whether or not the trial was effective in abolishing excessive daytime sleepiness. Nonetheless, most patients reported subjective improvement in their daytime symptoms and continued to use CPAP. Third, the results shown in this article would be applicable only for this specific commercial brand of APAP device, a finding that is of some importance since different performances have been reported for different APAP devices during the titration process. 32 In conclusion, the non-attended home APAP trial carried out with patients who have OSA and were evaluated by a simplified diagnostic approach proved effective in decreasing RDI. In addition, an acceptable adherence rate was seen. However, almost one-third of the patients continued to experience residual RDI > 10 events/h. While the health damage associated with residual OSA has yet to be determined, efforts should be made to assure an optimum positive airway pressure. Our results support that in up to one-third of patients, CPAP titration based on 95 th percentile pressure could prove insufficient if a residual RDI of < 10 events/h were established as a therapeutic target.
